Summary

The Peptic Ulcer Drugs Market is poised for significant growth over the forecast period, driven by various factors such as the rising prevalence of peptic ulcers, the increasing adoption of advanced treatment options, and the ongoing research and development in the field.In 2024, the market is valued at approximately USD 42.72 billion, with projections indicating it will reach USD 55.54 billion by 2031, growing at a compound annual growth rate (CAGR) of 3.80%. Peptic ulcers, which are open sores that develop on the lining of the stomach and the upper portion of the small intestine, are primarily caused by infection from Helicobacter pylori and the prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen sodium.

The primary symptom of peptic ulcers is stomach discomfort, and the condition is categorized into two types: gastric ulcers, which develop inside the stomach, and duodenal ulcers, which form in the upper part of the small intestine. While stress is often believed to contribute to peptic ulcers, it does not directly cause them, though it can exacerbate symptoms.

Peptic ulcer disease is a significant health concern, and various treatment options are available to manage the condition. The goal of treatment is to reduce stomach acid production, neutralize the acid present, and protect the ulcerated area to facilitate healing. The most common treatments include proton pump inhibitors (PPIs), H2-antagonists, antacids, and antibiotics.

Proton pump inhibitors, in particular, are widely used for treating peptic ulcers and have become the most popular form of treatment. These medications work by reducing the production of stomach acid, thereby promoting healing of the ulcer. PPI-based triple therapy has also been shown to enhance the eradication of Helicobacter pylori, a significant factor in the development of peptic ulcers.

Despite the availability of effective treatments, the market faces challenges that could impact its growth. One of the main concerns is the declining productivity of the drug pipeline, as many pharmaceutical companies have reduced their research and development budgets. As a result, these companies are focusing on creating prolonged-release formulations or combination therapies rather than developing new medications. This trend has led to a decrease in the innovation of novel treatments for peptic ulcers.

Moreover, the long-term use of proton pump inhibitors and antibiotics is associated with several risks, including an increased likelihood of hip fractures due to reduced calcium and iron absorption and a higher risk of secondary infections. These side effects are a significant concern for healthcare providers and patients alike.

Additionally, the market is affected by strict government regulations and the expiration of patents for key drugs. These factors contribute to the challenges faced by pharmaceutical companies in maintaining market share and profitability.

Despite these challenges, there are several opportunities for growth in the peptic ulcer drugs market. One of the key drivers is the increasing adoption of over-the-counter (OTC) drugs for the treatment of peptic ulcer disease. The availability of OTC medications makes healthcare more accessible and affordable for the general population, leading to higher acceptance and use of these drugs. Some of the commonly used OTC treatments include antacids, H2-receptor antagonists, and proton pump inhibitors.

The growing interest in alternative therapies, particularly phytotherapy, is another factor contributing to market growth. Phytotherapy involves the use of medicinal plants to treat various ailments, and there has been a significant rise in the adoption of herbal products for treating peptic ulcers. Medicinal herbs are considered a primary source of new drugs due to their potential to offer treatments with fewer side effects compared to traditional medications.

Geographically, the market is influenced by factors such as disease prevalence, lifestyle choices, and the availability of treatment options. For instance, in certain regions, the high prevalence of Helicobacter pylori infections and the widespread use of NSAIDs contribute to the high incidence of peptic ulcers. Additionally, lifestyle factors such as smoking, unhealthy diets, and stress play a role in the development of peptic ulcers.

The market dynamics also vary based on the distribution channels used to deliver treatments. Hospital pharmacies play a crucial role in the distribution of peptic ulcer drugs, as they provide access to medications for patients receiving treatment in hospitals. The rise in the number of patients diagnosed with peptic ulcers seeking treatment in hospitals has driven the demand for peptic ulcer medications in these settings. Additionally, the ease of accessing these medications in institutional settings contributes to the growth of this segment.

Private clinics, drug stores, retail pharmacies, and e-commerce platforms also play a significant role in the distribution of peptic ulcer drugs. The growing use of e-commerce for purchasing medications has provided patients with more convenient access to treatments, further boosting the market's growth.

The competition Analysis in the peptic ulcer drugs market is characterized by the presence of several key players actively involved in research and development. These companies are focused on obtaining certification approval for their products and launching new treatments in the market. For instance, certain pharmaceutical companies have explored the potential of existing medications to treat other conditions, such as using famotidine, a drug commonly used to treat stomach ulcers, to explore its effectiveness in treating other conditions.

Key Companies Covered

•Daewoong Pharmaceutical Co., Ltd.

•Takeda Pharmaceutical Company Limited

•Pfizer Inc.

•Abbott Laboratories

•AstraZeneca plc.

•Cadila Healthcare Ltd.

•Boehringer Ingelheim GmbH

•Eisai Co. Ltd.

•Yuhan Corporation

•GlaxoSmithKline plc.

Key Segments Covered in Peptic Ulcer Drugs Industry Research

Product:

•Proton Pump Inhibitors

•Potassium-Competitive Acid Blockers (P-CABs)

•Antacids

•H2- Antagonists

•Antibiotics

•Ulcer Protective

Indication:

•Gastritis

•Gastric Ulcers

•Duodenal Ulcers

•Gastroesophageal Reflux Disease (GERD)

Distribution Channel:

•Hospital Pharmacies

•Private Clinics

•Drug Stores

•Retail Pharmacies

•E-Commerce

Region:

•North America

•Latin America

•Europe

•South Asia

•East Asia

•Oceania

•Middle East and Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Peptic Ulcer Drugs Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. COVID-19 Impact Analysis
2.3.1. Supply
2.3.2. Demand
2.4. Value Chain Analysis
2.5. Porter’s Five Force Analysis
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Peptic Ulcer Drugs Market Outlook, 2018 – 2031
3.1. Global Peptic Ulcer Drugs Market Outlook, By Product, Value (US$ Bn), 2018 – 2031
3.1.1. Key Highlights
3.1.1.1. Antacids
3.1.1.2. Proton Pump Inhibitors
3.1.1.3. H2-Antagonists
3.1.1.4. Ulcer Protectives
3.1.1.5. Antibiotics
3.1.1.6. Potassium-Competitive Acid Blockers (P-CABs)
3.2. Global Peptic Ulcer Drugs Market Outlook, By Indication, Value (US$ Bn), 2018 – 2031
3.2.1. Key Highlights
3.2.1.1. Gastric Ulcers
3.2.1.2. Gastritis
3.2.1.3. Duodenal Ulcers
3.2.1.4. Gastroesophageal Reflux Disease (GERD)
3.3. Global Peptic Ulcer Drugs Market Outlook, By Distribution Channel, Value (US$ Bn), 2018 – 2031
3.3.1. Key Highlights
3.3.1.1. Hospital Pharmacies
3.3.1.2. Drug Stores
3.3.1.3. Retail Pharmacies
3.3.1.4. E-Commerce
3.4. Global Peptic Ulcer Drugs Market Outlook, by Region, Value (US$ Bn), 2018 – 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Peptic Ulcer Drugs Market Outlook, 2018 – 2031
4.1. North America Peptic Ulcer Drugs Market Outlook, By Product, Value (US$ Bn), 2018 – 2031
4.1.1. Key Highlights
4.1.1.1. Antacids
4.1.1.2. Proton Pump Inhibitors
4.1.1.3. H2-Antagonists
4.1.1.4. Ulcer Protectives
4.1.1.5. Antibiotics
4.1.1.6. Potassium-Competitive Acid Blockers (P-CABs)
4.2. North America Peptic Ulcer Drugs Market Outlook, By Indication, Value (US$ Bn), 2018 – 2031
4.2.1. Key Highlights
4.2.1.1. Gastric Ulcers
4.2.1.2. Gastritis
4.2.1.3. Duodenal Ulcers
4.2.1.4. Gastroesophageal Reflux Disease (GERD)
4.3. North America Peptic Ulcer Drugs Market Outlook, By Distribution Channel, Value (US$ Bn), 2018 – 2031
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacies
4.3.1.2. Drug Stores
4.3.1.3. Retail Pharmacies
4.3.1.4. E-Commerce
4.4. North America Peptic Ulcer Drugs Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
4.4.1.2. U.S. Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
4.4.1.3. U.S. Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
4.4.1.4. Canada Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
4.4.1.5. Canada Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
4.4.1.6. Canada Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Peptic Ulcer Drugs Market Outlook, 2018 – 2031
5.1. Europe Peptic Ulcer Drugs Market Outlook, By Product, Value (US$ Bn), 2018 – 2031
5.1.1. Key Highlights
5.1.1.1. Antacids
5.1.1.2. Proton Pump Inhibitors
5.1.1.3. H2-Antagonists
5.1.1.4. Ulcer Protectives
5.1.1.5. Antibiotics
5.1.1.6. Potassium-Competitive Acid Blockers (P-CABs)
5.2. Europe Peptic Ulcer Drugs Market Outlook, By Indication, Value (US$ Bn), 2018 – 2031
5.2.1. Key Highlights
5.2.1.1. Gastric Ulcers
5.2.1.2. Gastritis
5.2.1.3. Duodenal Ulcers
5.2.1.4. Gastroesophageal Reflux Disease (GERD)
5.3. Europe Peptic Ulcer Drugs Market Outlook, By Distribution Channel, Value (US$ Bn), 2018 – 2031
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacies
5.3.1.2. Drug Stores
5.3.1.3. Retail Pharmacies
5.3.1.4. E-Commerce
5.4. Europe Peptic Ulcer Drugs Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
5.4.1. Key Highlights
5.4.1.1. Germany Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
5.4.1.2. Germany Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
5.4.1.3. Germany Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.1.4. U.K. Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
5.4.1.5. U.K. Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
5.4.1.6. U.K. Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.1.7. France Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
5.4.1.8. France Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
5.4.1.9. France Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.1.10. Italy Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
5.4.1.11. Italy Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
5.4.1.12. Italy Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.1.13. Turkey Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
5.4.1.14. Turkey Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
5.4.1.15. Turkey Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.1.16. Russia Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
5.4.1.17. Russia Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
5.4.1.18. Russia Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.1.19. Rest of Europe Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
5.4.1.20. Rest of Europe Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
5.4.1.21. Rest of Europe Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Peptic Ulcer Drugs Market Outlook, 2018 – 2031
6.1. Asia Pacific Peptic Ulcer Drugs Market Outlook, By Product, Value (US$ Bn), 2018 – 2031
6.1.1. Key Highlights
6.1.1.1. Antacids
6.1.1.2. Proton Pump Inhibitors
6.1.1.3. H2-Antagonists
6.1.1.4. Ulcer Protectives
6.1.1.5. Antibiotics
6.1.1.6. Potassium-Competitive Acid Blockers (P-CABs)
6.2. Asia Pacific Peptic Ulcer Drugs Market Outlook, By Indication, Value (US$ Bn), 2018 – 2031
6.2.1. Key Highlights
6.2.1.1. Gastric Ulcers
6.2.1.2. Gastritis
6.2.1.3. Duodenal Ulcers
6.2.1.4. Gastroesophageal Reflux Disease (GERD)
6.3. Asia Pacific Peptic Ulcer Drugs Market Outlook, By Distribution Channel, Value (US$ Bn), 2018 – 2031
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacies
6.3.1.2. Drug Stores
6.3.1.3. Retail Pharmacies
6.3.1.4. E-Commerce
6.4. Asia Pacific Peptic Ulcer Drugs Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
6.4.1. Key Highlights
6.4.1.1. China Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
6.4.1.2. China Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
6.4.1.3. China Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
6.4.1.4. Japan Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
6.4.1.5. Japan Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
6.4.1.6. Japan Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
6.4.1.7. South Korea Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
6.4.1.8. South Korea Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
6.4.1.9. South Korea Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
6.4.1.10. India Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
6.4.1.11. India Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
6.4.1.12. India Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
6.4.1.13. Southeast Asia Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
6.4.1.14. Southeast Asia Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
6.4.1.15. Southeast Asia Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
6.4.1.16. Rest of Asia Pacific Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
6.4.1.17. Rest of Asia Pacific Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
6.4.1.18. Rest of Asia Pacific Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Peptic Ulcer Drugs Market Outlook, 2018 – 2031
7.1. Latin America Peptic Ulcer Drugs Market Outlook, By Product, Value (US$ Bn), 2018 – 2031
7.1.1. Key Highlights
7.1.1.1. Antacids
7.1.1.2. Proton Pump Inhibitors
7.1.1.3. H2-Antagonists
7.1.1.4. Ulcer Protectives
7.1.1.5. Antibiotics
7.1.1.6. Potassium-Competitive Acid Blockers (P-CABs)
7.2. Latin America Peptic Ulcer Drugs Market Outlook, By Indication, Value (US$ Bn), 2018 – 2031
7.2.1. Key Highlights
7.2.1.1. Gastric Ulcers
7.2.1.2. Gastritis
7.2.1.3. Duodenal Ulcers
7.2.1.4. Gastroesophageal Reflux Disease (GERD)
7.3. Latin America Peptic Ulcer Drugs Market Outlook, By Distribution Channel, Value (US$ Bn), 2018 – 2031
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacies
7.3.1.2. Drug Stores
7.3.1.3. Retail Pharmacies
7.3.1.4. E-Commerce
7.4. Latin America Peptic Ulcer Drugs Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
7.4.1.2. Brazil Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
7.4.1.3. Brazil Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
7.4.1.4. Mexico Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
7.4.1.5. Mexico Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
7.4.1.6. Mexico Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
7.4.1.7. Argentina Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
7.4.1.8. Argentina Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
7.4.1.9. Argentina Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
7.4.1.10. Rest of Latin America Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
7.4.1.11. Rest of Latin America Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
7.4.1.12. Rest of Latin America Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Peptic Ulcer Drugs Market Outlook, 2018 – 2031
8.1. Middle East & Africa Peptic Ulcer Drugs Market Outlook, By Product, Value (US$ Bn), 2018 – 2031
8.1.1. Key Highlights
8.1.1.1. Antacids
8.1.1.2. Proton Pump Inhibitors
8.1.1.3. H2-Antagonists
8.1.1.4. Ulcer Protectives
8.1.1.5. Antibiotics
8.1.1.6. Potassium-Competitive Acid Blockers (P-CABs)
8.2. Middle East & Africa Peptic Ulcer Drugs Market Outlook, By Indication, Value (US$ Bn), 2018 – 2031
8.2.1. Key Highlights
8.2.1.1. Gastric Ulcers
8.2.1.2. Gastritis
8.2.1.3. Duodenal Ulcers
8.2.1.4. Gastroesophageal Reflux Disease (GERD)
8.3. Middle East & Africa Peptic Ulcer Drugs Market Outlook, By Distribution Channel, Value (US$ Bn), 2018 – 2031
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacies
8.3.1.2. Drug Stores
8.3.1.3. Retail Pharmacies
8.3.1.4. E-Commerce
8.4. Middle East & Africa Peptic Ulcer Drugs Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
8.4.1. Key Highlights
8.4.1.1. GCC Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
8.4.1.2. GCC Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
8.4.1.3. GCC Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
8.4.1.4. South Africa Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
8.4.1.5. South Africa Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
8.4.1.6. South Africa Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
8.4.1.7. Egypt Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
8.4.1.8. Egypt Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
8.4.1.9. Egypt Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
8.4.1.10. Nigeria Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
8.4.1.11. Nigeria Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
8.4.1.12. Nigeria Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
8.4.1.13. Rest of Middle East & Africa Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 – 2031
8.4.1.14. Rest of Middle East & Africa Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 – 2031
8.4.1.15. Rest of Middle East & Africa Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 – 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Market Share Analysis, 2022
9.2. Competitive Dashboard
9.3. Company Profiles
9.3.1. Takeda Pharmaceutical Company Limited
9.3.1.1. Company Overview
9.3.1.2. Product Portfolio
9.3.1.3. Financial Overview
9.3.1.4. Business Strategies and Development
9.3.2. Pfizer, Inc.
9.3.2.1. Company Overview
9.3.2.2. Product Portfolio
9.3.2.3. Financial Overview
9.3.2.4. Business Strategies and Development
9.3.3. AstraZeneca plc.
9.3.3.1. Company Overview
9.3.3.2. Product Portfolio
9.3.3.3. Financial Overview
9.3.3.4. Business Strategies and Development
9.3.4. Cadila Healthcare Ltd.
9.3.4.1. Company Overview
9.3.4.2. Product Portfolio
9.3.4.3. Financial Overview
9.3.4.4. Business Strategies and Development
9.3.5. Eisai Co. Ltd.
9.3.5.1. Company Overview
9.3.5.2. Product Portfolio
9.3.5.3. Financial Overview
9.3.5.4. Business Strategies and Development
9.3.6. Yuhan Corporation
9.3.6.1. Company Overview
9.3.6.2. Product Portfolio
9.3.6.3. Financial Overview
9.3.6.4. Business Strategies and Development
9.3.7. GSK
9.3.7.1. Company Overview
9.3.7.2. Product Portfolio
9.3.7.3. Financial Overview
9.3.7.4. Business Strategies and Development
9.3.8. Daewoong Pharmaceutical Co., Ltd.
9.3.8.1. Company Overview
9.3.8.2. Product Portfolio
9.3.8.3. Financial Overview
9.3.8.4. Business Strategies and Development
9.3.9. Abbott
9.3.9.1. Company Overview
9.3.9.2. Product Portfolio
9.3.9.3. Financial Overview
9.3.9.4. Business Strategies and Development
9.3.10. Boehringer Ingelheim GmbH
9.3.10.1. Company Overview
9.3.10.2. Product Portfolio
9.3.10.3. Financial Overview
9.3.10.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations